Apolipoproteins A1, B, and apoB/apoA1 ratio are associated with first ST-segment elevation myocardial infarction but not with recurrent events during long-term follow-up

Quantifying Atherogenic Lipoproteins: Current and Future Challenges in the Era of Personalized Medicine and Very Low Concentrations of LDL Cholesterol. A Consensus Statement from EAS and EFLM

(2018) Michel R. Langlois et al.   CLINICAL CHEMISTRY

Lipids, Lipoproteins, and Metabolites and Risk of Myocardial Infarction and Stroke

(2018) Michael V. Holmes et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Residual atherosclerotic cardiovascular disease risk in statin-treated adults: The Multi-Ethnic Study of Atherosclerosis

(2017) Nathan D. Wong et al.   Journal of Clinical Lipidology

Low levels of apolipoprotein-CII in normotriglyceridemic patients with very premature coronary artery disease: Observations from the MISSION! Intervention study

(2017) Maaike P.J. Hermans et al.   Journal of Clinical Lipidology

Very-Low-Density Lipoprotein–Associated Apolipoproteins Predict Cardiovascular Events and Are Lowered by Inhibition of APOC-III

(2017) Raimund Pechlaner et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

(2017) Marc S. Sabatine et al.   NEW ENGLAND JOURNAL OF MEDICINE

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

(2017) Paul M Ridker et al.   NEW ENGLAND JOURNAL OF MEDICINE

Fasting Is Not Routinely Required for Determination of a Lipid Profile: Clinical and Laboratory Implications Including Flagging at Desirable Concentration Cutpoints--A Joint Consensus Statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine

(2016) B. G. Nordestgaard et al.   CLINICAL CHEMISTRY

Atorvastatin treatment and LDL cholesterol target attainment in patients at very high cardiovascular risk

(2016) Ulrich Laufs et al.   Clinical Research in Cardiology

2016 ESC/EAS Guidelines for the Management of Dyslipidaemias

(2016) Alberico L. Catapano et al.   EUROPEAN HEART JOURNAL

Circulating Apolipoprotein E Concentration and Cardiovascular Disease Risk: Meta-analysis of Results from Three Studies

(2016) Reecha Sofat et al.   PLOS MEDICINE

Age and Cardiovascular Risk Attributable to Apolipoprotein B, Low‐Density Lipoprotein Cholesterol or Non‐High‐Density Lipoprotein Cholesterol

(2016) Allan D. Sniderman et al.   Journal of the American Heart Association

Automated Multiplex LC-MS/MS Assay for Quantifying Serum Apolipoproteins A-I, B, C-I, C-II, C-III, and E with Qualitative Apolipoprotein E Phenotyping

(2015) I. van den Broek et al.   CLINICAL CHEMISTRY

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes

(2015) Christopher P. Cannon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Apolipoprotein B improves risk assessment of future coronary heart disease in the Framingham Heart Study beyond LDL-C and non-HDL-C

(2015) Michael J Pencina et al.   European Journal of Preventive Cardiology

Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: Rationale and design of the ODYSSEY Outcomes trial

(2014) Gregory G. Schwartz et al.   AMERICAN HEART JOURNAL

Relations of Change in Plasma Levels of LDL‐C, Non‐HDL‐C and apoB With Risk Reduction From Statin Therapy: A Meta‐Analysis of Randomized Trials

(2014) George Thanassoulis et al.   Journal of the American Heart Association

2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults

(2013) Neil J. Stone et al.   CIRCULATION

Determinants of Residual Risk in Secondary Prevention Patients Treated With High- Versus Low-Dose Statin Therapy

(2012) Samia Mora et al.   CIRCULATION

ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation

(2012) et al.   EUROPEAN HEART JOURNAL

Remnant Cholesterol as a Causal Risk Factor for Ischemic Heart Disease

(2012) Anette Varbo et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

A Meta-Analysis of Low-Density Lipoprotein Cholesterol, Non-High-Density Lipoprotein Cholesterol, and Apolipoprotein B as Markers of Cardiovascular Risk

(2011) Allan D. Sniderman et al.  

Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management

(2011) M. John Chapman et al.   EUROPEAN HEART JOURNAL

Apolipoprotein B/A-I and total cholesterol/high-density lipoprotein cholesterol ratios both predict cardiovascular events in the general population independently of nonlipid risk factors, albuminuria and C-reactive protein

(2010) P. J. W. H. Kappelle et al.   JOURNAL OF INTERNAL MEDICINE

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials

(2010)   LANCET

Apolipoprotein B and Cardiovascular Disease Risk: Position Statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices

(2009) J. H. Contois et al.   CLINICAL CHEMISTRY

A systematic review and meta-analysis on the therapeutic equivalence of statins

(2009) T.-C. Weng et al.   JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS

Minor Injuries as a Risk Factor for Venous Thrombosis

(2008) Karlijn J. van Stralen   ARCHIVES OF INTERNAL MEDICINE

The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patients

(2008) Jean-Charles Fruchart et al.   Diabetes & Vascular Disease Research

Sirolimus-Eluting Stents Versus Bare-Metal Stents in Patients With ST-Segment Elevation Myocardial Infarction: 9-Month Angiographic and Intravascular Ultrasound Results and 12-Month Clinical Outcome

(2008) Bas L. van der Hoeven et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Lipoprotein Management in Patients With Cardiometabolic Risk

(2008) John D. Brunzell et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study

(2008) Matthew J McQueen et al.   LANCET

Use of Multiple Biomarkers to Improve the Prediction of Death from Cardiovascular Causes

(2008) Björn Zethelius et al.   NEW ENGLAND JOURNAL OF MEDICINE